Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetyl Penicillamine SCHEMBL34351 | 1.00 | MAPT (0.43) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetyl Penicillamine SCHEMBL4468919 | 1.00 | MAPT (0.43) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetyl Penicillamine SCHEMBL15106832 | 0.92 | ALDH1A1 (0.41) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetyl Penicillamine SCHEMBL8398514 | 0.85 | ALDH1A1 (0.39) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL1236539 | 0.81 | CA2 (0.42) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL8415890 | 0.81 | CA2 (0.42) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL2515799 | 0.81 | CA2 (0.42) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL929561 | 0.80 | MAPT (0.58) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL3680194 | 0.80 | MAPT (0.37) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL21816921 | 0.80 | ALDH1A1 (0.41) | MAPTKDM4EALDH1A1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070151-A | Nitric oxide generating/releasing medical device | 斯特里莱国家有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | claimed |
| US-20250281531-A1 | METHODS AND COMPOSITIONS FOR DETOXIFICATION OF CHRONIC EXPOSURE TO TOXINS | MDLifespan Enterprises, LLC | 2025-09-11 | — | — | US | claimed |
| WO-2025078955-A1 | WATER-BASED NITRIC OXIDE GENERATING/RELEASING MATERIALS | STERILE STATE, LLC (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025078956-A1 | NITRIC OXIDE GENERATING/RELEASING MEDICAL DEVICES | STERILE STATE, LLC (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4337197-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-03-20 | — | — | EP | claimed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | claimed |
| EP-4161598-A1 | DEVICE FOR PROVIDING THERAPEUTIC GAS | Biocrede Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| CN-113876950-B | Microneedle patch suitable for NO-synergetic photodynamic therapy and preparation method thereof | 浙江大学 | 2023-02-10 | — | — | CN | claimed |
| WO-2022187702-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED RESPIRATORY INFECTIONS | PHILERA NEW ZEALAND (NZ) | 2022-09-09 | — | — | WO | claimed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | claimed |
| WO-2003013499-A2 | DRUGS FOR VASCULOPATIES | NICOX S.A. (FR) | 2003-02-20 | — | — | WO | claimed |
| WO-2003000642-A2 | DRUGS FOR CHRONIC PAINS | NICOX S.A. (FR) | 2003-01-03 | — | — | WO | claimed |
| WO-2002100400-A1 | ORGANIC NITRATE-BASED COMPOUNDS FOR THE TREATMENT OF VASCULOPATHIES | NICOX S.A. (FR) | 2002-12-19 | — | — | WO | claimed |
| WO-2002092072-A2 | DRUGS FOR THE TREATMENT OF THE ALZHEIMER DISEASE | NICOX S.A. (FR) | 2002-11-21 | — | — | WO | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| EP-1169030-A1 | AGENTS AND METHODS FOR PROMOTING PRODUCTION GAINS IN ANIMALS | The Horticulture and Food Research Institute of New Zealand Limited (NZ) | 2002-01-09 | — | — | EP | claimed |
| WO-2000054766-A1 | AGENTS AND METHODS FOR PROMOTING PRODUCTION GAINS IN ANIMALS | THE HORTICULTURE AND FOOD RESEARCH INSTITUTE OF NEW ZEALAND LIMITED (NZ) | 2000-09-21 | — | — | WO | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | MAPT 1646/4885KDM4E 2777/4885THRB 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.